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Abstract
Background: To determine the impact of the quality of pre-dialysis nephrological care on health-related quality of
life (HRQoL) at dialysis onset, which has not been well evaluated.
Methods: All adults who began a dialysis treatment in the administrative region of Lorraine (France) in 2005 or
2006, were enrolled in this prospective observational study.
HRQoL was measured using the Kidney Disease Quality of Life V36 questionnaire, which enables calculation of two
generic (physical and mental) and three specific dimensions (Symptoms/problems, Effects and Burden of kidney
disease). The specific dimensions were scored from 0 to 100 (worst to best possible functioning). Pre-dialysis
nephrological care was measured using three indicators: quality of therapeutic practices (evaluated across five main
aspects: hypertension/proteinuria, anemia, bone disease, metabolic acidosis and dyslipidemia), time since referral to
a nephrologist and number of nephrology consultations in the year preceding dialysis treatment.
Results: Two thousand and eighty-three (67.4%) patients were referred to a nephrologist more than 1 month
before dialysis initiation and completed the HRQoL questionnaire. Quality of therapeutic practices was significantly
associated with the Mental component. Time since referral to a nephrologist was associated with Symptoms/
problems and the Effects of kidney disease dimensions, but no relationship was found between the number of
nephrology consultations and HRQoL.
Conclusions: HRQoL at dialysis onset is significantly influenced by the quality of pre-dialysis nephrological care.
Therefore, disease management should be emphasized.
Background
Although the correlation between chronic kidney disease
(CKD) and risk of cardiovascular morbidity and mortal-
ity has been thoroughly investigated, studies evaluating
the impact of CKD on health-related quality of life
(HRQOL) are somewhat scarce [1-3]. In particular, the
relationship between quality of pre-dialysis care and
HRQoL at dialysis onset has not been investigated to
date. However, numerous studies have shown associa-
tions between quality of pre-dialysis care and dialysis
mortality on one hand [4] and, HRQoL at dialysis onset
and dialysis mortality on the other hand [5-7].
The quality of pre-dialysis care is a multidimensional
concept that includes several aspects, for example, clini-
cal follow-up by nephrologists, the quality of therapeutic
care, the quality of dialysis preparation, and counselling.
A positive association between early referral to a
nephrologist and survival after starting renal replace-
ment therapy (RRT) has been clearly demonstrated [8]
but the impact of early referral on HRQoL at initiation
of dialysis is still a matter for debate [2,9]. Moreover,
the lack of a consensus over the definition of ‘early’ and
‘late’ nephrology referral has left primary care providers
unsure about the optimum timing and pattern of
nephrology care. Nephrological care was recently
assessed from a quantitative rather than a qualitative
perspective, focusing on the number of nephrology
consultations before RRT [10]. Moreover, a favourable
association between early referral or a high number of
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pre-ESRD nephrology consultations and quality of thera-
peutic care has been suggested [11,12]. Likewise, quality
of pre-ESRD therapeutic practices has been found to be
associated with survival after RRT [4].
We used data from the pharmacoepidemiologic AVE-
NIR (AVantagE de la Néphroprotection dans l’Insuffi-
sance Rénale) study to explore the impact on HRQoL at
dialysis onset of three pre-dialysis indicators of quality of
care: quality of therapeutic practices, time since referral
to a nephrologist and number of nephrology consulta-
tions during the year preceding dialysis. Our hypothesis
is that the higher the quality of pre-dialysis care, the bet-
ter the HRQoL. Our aim is to heighten nephrologists’
awareness of the outstanding importance of the quality of
pre-dialysis care.
Methods
Setting, study design and sample selection
The AVENIR study was an observational cohort study
involving 12 private and public nephrology units operat-
ing in the administrative region of Lorraine, northeast
France (population of 2,339,000, according to the 2006
census). Its methodology was approved by the ethics
committee of the regional university hospital and is
described in detail elsewhere [11].
All adults with CKD who began a dialysis treatment in
one of the 12 units between January 1, 2005, and
December 31, 2006, were identified from the regional
ESRD registry (REIN registry) and enrolled in the AVE-
NIR study. Patients with reversible renal failure and
those returning to dialysis following kidney graft failure
were not included. The present analysis focuses on the
impact of several features of pre-dialysis nephrological
care on HRQoL of ESRD patients referred to a nephrol-
ogist at least 1 month before the start of dialysis.
Data collection and definitions
A standardized form was used to retrospectively collect
demographic, clinical, biological and therapeutic data
from outpatient medical records. Demographic and
clinical data (except for blood pressure) were from
inclusion in the REIN registry. Blood pressure readings,
as well as biological and therapeutic data covered the
observation period from the day of the first nephrology
consultation to dialysis onset, and were used to evalu-
ate the quality of therapeutic practices. Demographic
and clinical variables used as adjustment factors in the
analysis included age, gender, body mass index (BMI),
primary renal disease and the presence (or absence) of
at least one co-morbidity. BMI was calculated as
weight (kg)/square of height (m). Primary renal disease
was categorized into five groups: glomerulonephritis,
diabetic or hypertensive nephropathy, hereditary
nephropathy and others. Co-morbidity was defined as
the presence of clinically significant non-renal disease
(e.g. cardiac disease, vascular disease, respiratory dis-
ease, diabetes mellitus and malignancy).
In addition, all patients who began a dialysis treatment
had to complete a HRQoL questionnaire as soon as possi-
ble after their first session, and within the first 3 months
of replacement therapy.
Quality of therapeutic practices
The appropriateness of pre-dialysis therapeutic practices
was assessed in terms of adherence to current guidelines
[13-17] covering five main aspects of therapeutic care in
CKD: hypertension/proteinuria, anemia, bone disease,
metabolic acidosis and dyslipidemia. A practice was con-
sidered inappropriate if one treatment was not prescribed
when it was indicated for a biological or clinical reason;
otherwise, the practice was considered appropriate
(Table 1). For example, hypertensive care was recorded
as inappropriate for a patient not given antihypertensive
medication when his or her mean blood pressure during
the observation period was >130/80 mmHg. More
detailed information has been published elsewhere [11].
The quality of therapeutic practices was then esti-
mated for each patient in terms of the number of
aspects (out of the five above) being managed appropri-
ately. Quality of practices was considered to be High
when four or five aspects were appropriately managed,
Moderate when including two or three aspects and
finally Poor when none or just one aspect was appropri-
ately managed.
Pre-dialysis nephrology care
Pre-dialysis nephrology care was assessed in terms of
the timing of referral to a nephrologist before dialysis
onset and the number of nephrology consultations dur-
ing the year preceding dialysis treatment.
Patients were classified into three groups according
to their timing of referral to a nephrologist as follows:
more than 12 months before dialysis onset (early refer-
ral), less than 12 months and more than 4 months
(intermediate referral), and less than 4 months and
more than 1 month (late referral). The number of
nephrology consultations during the year preceding
dialysis was categorized into three groups: 0 to 2 con-
sultations, 3 to 5 consultations, and 6 consultations or
more.
Outcome of interest
HRQoL was measured with the French version of the
‘Kidney Disease Quality of Life’ (KDQoL) V36 question-
naire [18]. This instrument includes a 12-item health
survey as the generic core (SF12), supplemented with
multi-item scales targeted at particular concerns of
patients with kidney disease and on dialysis.
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The 12 items of SF12 - a shorter version of the gen-
eric SF36 instrument - may be combined into two sum-
mary measures: Physical (PCS12) and Mental (MCS12)
Component Summary Scales [19]. They are computed
to have means of 50 and standard deviations of 10 in a
general US population. The specific items may be sum-
marized into three dimensions: symptoms/problems (12
items), effects of kidney disease on daily life (8 items),
and burden of kidney disease (4 items) [20]. All these
specific dimensions, scored from 0 to 100 (worst to best
possible functioning), are calculated as the mean of item
values when no more than half of the items are missing.
Otherwise, scores are recorded as missing.
We calculated the Cronbach coefficient of the three
specific dimensions, confirming their internal consis-
tency in our sample (0.76, 0.77 and 0.79 for Symptoms,
Effects and Burden dimensions, respectively).
Statistical Analysis
Descriptive statistics were used to assess patients’ charac-
teristics according to whether or not they had completed
the KDQoL questionnaire (respondents/non-respondents).
Continuous variables are presented as means ± standard
deviations and categorical variables as percentages.
Comparisons between respondents and non-respondents
were made using the Pearson Chi2 test and analysis of var-
iance for categorical and continuous variables, respectively.
Analysis of variance models were used to explore the
impact of the three pre-dialysis indicators defined above
on each HRQoL score at dialysis onset in a bivariable
analysis. Indicators significantly associated with HRQoL
in the bivariable analysis were then candidates in a
multivariable analysis of variance model, adjusted for the
main patient characteristics known to be associated with
HRQoL in CKD (age, gender, BMI, primary renal disease,
co-morbidity) [21-24] and the nephrology unit. The
HRQoL scores are reported as means ± standard errors
and P-value. A P-value of < 0.05 for two-sided tests was
considered significant. All analyses were performed with
SAS version 9.1 (SAS Institute, Inc., Cary, N.C).
Results
Patient characteristics
On the 566 patients enrolled in the AVENIR study, 420
were referred to a nephrologist more than 1 month
before dialysis initiation and are considered here. Among
them, 137 did not complete the KDQoL questionnaire at
all (n = 99) or completed it after the third month of dia-
lysis treatment (n = 38). Thus, 283 patients completed
the KDQoL questionnaire as indicated and were consid-
ered as respondents (response rate= 67.4%).
Table 2 shows the characteristics of included patients
overall (n = 420) and by respondent status. Among
respondent patients, the mean age was 67.1 ± 14.6 years,
and 63.3% were male. Hypertension and diabetes were the
leading causes of CKD, and 44.2% of respondents had at
least one co-morbidity. The average length of pre-dialysis
nephrological care was 43.0 ± 51.9 months, and nearly half
of these patients received between 3 and 5 nephrology
consultations during the year preceding dialysis.
As compared with non-respondents, respondents
were younger (P = 0.03). They also tended to have more
pre-dialysis nephrology consultations and were more
likely to be referred early to a nephrologist than non-
Table 1 Definition of ‘Inappropriate therapeutic care’ and percentage of patients being managed appropriately by
therapeutic aspect evaluated (n = 420 included) [10]
Therapeutic fields
evaluated
Definition of ‘Inappropriate therapeutic care’ % of patients being managed
appropriately
Hypertension/
Proteinuria
Mean BPa >130/80 mmHg without prescription of an antihypertensive agent 72.4
Mean proteinuria >0.5 g/dl without prescription of a renin-angiotensin system inhibitor
Anemia Hemoglobin <11 g/dl in two successive readings without prescription of an
erythropoiesis-stimulating agent
Erythropoiesis-stimulating therapy without prescription of iron 56.2
Or
Mean serum ferritin <100 ng/ml without prescription of iron (in patients not given
erythropoiesis-stimulating therapy)
Bone disease Mean serum calcium <10.2 mg/dl without prescription of calcium 16.7
Mean serum 25-hydroxyvitamin D <30 ng/ml without prescription of ergocalciferol
Or
Mean serum 25-hydroxyvitamin D >30 ng/ml and hyperparathyroidism without
prescription of alfacalcidol
Metabolic acidosis Mean serum bicarbonates <23 mEq/l without prescription of bicarbonate 60.2
Dyslipidemia Mean fasting total cholesterol >201 mg/dl or mean triglycerides >150.5 mg/dl without
prescription of a lipid-lowering therapy
61.4
a BP, blood pressure.
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respondents, but these differences did not reach
significance.
HRQoL results
Table 3 shows that HRQoL measured by the SF12 was
altered in its physical (PCS12) and mental (MCS12)
components: respectively -10.5 and -7.1 points, as
compared with the general US population and -10.8 and
-4.3 points, as compared with the general French popu-
lation [25]. The specific scores varied from 41.1 points
for the dimension ‘Burden of kidney disease’ to 67.9
points for ‘Symptoms/problems’.
Impact of quality of therapeutic practices and
pre-dialysis nephrology care on HRQoL
Table 4 presents HRQoL scores for pre-dialysis indica-
tors that were significantly associated with HRQoL
dimensions in the multivariable analysis. The Physical
Component was influenced by none of the three pre-
dialysis indicators. Quality of therapeutic practices was
significantly associated with the Mental Component: the
higher the quality of practices, the better the MCS12
score (High quality vs. Poor = +3.8 points, P = 0.01).
Time since referral to a nephrologist was associated
with two specific dimensions: ‘Symptoms/problems’ and
‘Effects of kidney disease’. The longer the pre-dialysis
nephrological follow-up, the better the score related to
‘Symptoms/problems’ (>12 months vs. 1 to 4 months =
+10.9 points, P = 0.001, and 4-12 months vs. 1 to 4
months = +10.5 points, P = 0.007) and the better the
score of ‘Effects of kidney disease’ (>12 months vs. 1 to
4 months = +8.4 points, P = 0.03). The number of
nephrology consultations during the year preceding dia-
lysis was associated with none of the five dimensions of
HRQoL.
When limiting the analyses to subjects who completed
the HRQoL questionnaire within 30 days after dialysis
onset (n = 211), all the previously observed associations
remained statistically significant. Results remained
unchanged too when analyses were re-run with only
subjects who completed the questionnaire within the
first 10 days after dialysis onset (n = 120).
Discussion
To our knowledge, this observational study is the first to
explore in depth the association between the quality of
pre-ESRD nephrological care, evaluated across three
indicators, and HRQoL at dialysis onset. In a field where
randomized controlled studies cannot be ethically
designed, our results suggest: first, a mild, but
Table 2 Characteristics of included patients according to
their respondent status
Overall
(N = 420)
Respondents
YES
(N = 283)
NO
(N = 137)
P
Male sex (%) 61.0 63.3 56.2 0.17
Age at dialysis onset, year
m ± SD 68.2 ± 14.8 67.1 ± 14.6 70.5 ± 15.1 0.03
<45 (%) 8.6 9.2 7.3 0.06
45 - 64 (%) 23.8 26.9 17.5
≥65 (%) 67.6 64.0 75.2
Body mass index ≥ 25
kg/m2 (%)
59.8 60.8 57.7 0.55
Primary renal disease (%)
Glomerulonephritis 10.3 11.3 8.1 0.55
Diabetic
nephropathy
22.7 20.5 27.2
Hypertensive
nephropathy
23.6 24.4 22.1
Hereditary
nephropathy
5.5 5.7 5.7
Others 37.9 38.2 37.5
Comorbid condition (%) 47.1 44.2 53.3 0.08
Quality of therapeutic
practices (%)
High 22.1 23.7 19.0 0.12
Moderate 65.7 62.5 72.3
Poor 12.1 13.8 8.8
Time since referral to a
nephrologist, months
m ± SD 42.0 ± 52.3 43.0 ± 51.9 39.9 ± 53.2 0.57
>12 (%) 69.3 72.8 62.0 0.07
[4 - 12[ (%) 17.9 16.3 21.2
[1 - 4[ (%) 12.9 11.0 16.8
Number of nephrology
consultations (%)
6 or more 24.6 28.0 17.5 0.06
3 - 5 49.2 47.2 53.3
0 - 2 26.3 24.8 29.2 Table 3 HRQoL scores at dialysis initiation (N = 283
respondents)
HRQoL scores N Mean Standard Error
Physical (PCS12) 248 39.5 5.8
Mental (MCS12) 248 42.9 7.0
Symptoms/problems 278 67.9 16.8
Effects of kidney disease 280 61.2 20.3
Burden of kidney disease 278 41.1 23.6
Abbreviations: HRQoL, health related quality of life; PCS, physical component
summary; MCS, mental component summary.
Boini et al. Health and Quality of Life Outcomes 2011, 9:7
http://www.hqlo.com/content/9/1/7
Page 4 of 7
statistically significant, association between quality of
therapeutic practices, evaluated across five therapeutic
aspects, and mental, but not physical, quality of life; sec-
ond, the earlier the referral to a nephrologist, the better
the control of symptoms, problems and effects of CKD;
third, a lack of association between the number of
nephrology consultations and HRQoL.
HRQoL was measured with the validated French ver-
sion of the KDQoL V36 [20]. The two generic scores
allowed ESRD patients to be compared with the general
population, whereas the three specific scores explored
the impact of the kidney disease on daily life. Both phy-
sical and mental summary scores were well below 50,
which is the expected average from the US general
population. These results are consistent with previous
studies [1,7]. Moreover, HRQoL at dialysis onset was
altered compared to the French general population, par-
ticularly the physical component [25]. Disease-specific
scores observed in our ESRD sample were close to
scores reported by Molsted et al [26], but well below
than those observed by Mujais et al [27] in their CKD
stage V patients. Nevertheless, in this last study, HRQoL
was measured when patients were not yet under dialysis
treatment, which seems to have a marked impact on the
specific dimensions of HRQoL, particularly the ‘Burden
of kidney disease’. In any case, this dimension was
always the most impaired HRQoL dimension in CKD or
ESRD patients. This emphasises the need for psychologi-
cal support of ESRD patients at dialysis onset.
Previous studies using the SF36 suggest that scores in
the range of 2 or 3 points on the physical and mental
summary scores (equivalent to 0.2 to 0.3 SD) are likely
to be clinically important [28]. We observed, in the
MCS12 score, differences according to the level of qual-
ity of therapeutic practices that were around 2 to 4
points, suggesting that they are likely to be noticeable
and meaningful to patients at dialysis initiation. As per-
ceived mental health is an independent predictor of
mortality and morbidity [7], attaining the target
of MCS12 score observed in patients with high quality
of therapeutic practices is of interest. No other study to
date has investigated the impact of the quality of pre-
ESRD therapeutic practices on HRQoL at dialysis
initiation.
Concerning the impact of time since referral to a
nephrologist on HRQoL, results from previous studies
are conflicting [1,9]. Sesso and Yoshihiro [9] have
demonstrated that patients referred late to a nephrolo-
gist (≤ one month before starting dialysis) have signifi-
cantly worse HRQoL than those referred early (≥ 6
months). We found similar tendencies in two of the
three specific HRQoL dimensions (symptoms and
effects) but no comparison can be made in HRQoL
scores because Sesso and Yoshihiro used another quality
of life questionnaire (Kidney Disease Questionnaire).
These associations we found between time referral to a
nephrologist and specific dimensions of HRQoL may
reflect the benefit of the nephrologist’s having had more
time to evaluate and treat properly somatic symptoms
and consequences of CKD on his patients. Conversely,
Caskey et al found no significant difference between
early and late referral patients in any of the SF36 sum-
mary scores or domain scores [1]. However, in this
study, patients were considered ‘early referred’ if they
Table 4 Impact of quality of therapeutic practices and pre-dialysis nephrology care on HRQoL (N = 283 respondents)
PCS12 MCS12 Symptoms/
problems
Effects of kidney
disease
Burden of kidney
disease
Mean* SE P Mean* SE P Mean* SE P Mean* SE P Mean* SE P
Quality of therapeutic practices 0.006 0.006 NS 0.05 NS NS NS
High 44.6 1.0 0.01
Moderate 42.8 0.7 0.13
Poor 40.8 1.3 ref.
Time since referral to a nephrologist NS NS 0.004 0.09 NS
>12 months 69.9 1.5 0.001 63.5 1.8 0.03
[4 - 12] 69.5 2.7 0.007 62.9 3.2 0.09
[1 - 4] 59.0 3.2 ref. 55.1 3.9 ref.
Number of nephrology consultations NS NS NS NS NS
6 or more
3 - 5
0 - 2
Abbreviations: HRQoL, health related quality of life; PCS, physical component summary; MCS, mental component summary; SE, standard error; NS, not significant.
*Model adjusted for age, gender, BMI, primary renal disease, presence of co-morbidity, and nephrology unit.
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had been followed by a nephrologist for >1 month
before their first dialysis. As we considered early
referred patients those who had been followed for more
than 12 months before dialysis onset, the results are not
comparable. The main difficulty in comparing results of
studies investigating the time of referral to a nephrolo-
gist is the use of multiple definitions of ‘early’ and ‘late’.
Another way of assessing pre-ESRD nephrological care
is to consider the frequency of nephrology consultations
before RRT rather than timing of referral [10]. In our
study, we found no association between the number of
nephrology consultations during the year preceding RRT
and HRQoL at initiation of dialysis. Studies published to
date have investigated the relationship between the fre-
quency of patient-nephrologist visits during mainte-
nance dialysis and HRQoL [10,29] but none has looked
at the impact on HRQoL of frequency of visits before
RRT. Moreover, neither Plantinga et al [10] nor Mentari
et al [29] found any association between the frequency
of patient-nephrologist contact and HRQoL of dialyzed
patients.
Some possible limitations should be considered when
interpreting our findings. First, as this study was obser-
vational, it allows us to measure associations between
pre-dialysis indicators and HRQoL, but cannot demon-
strate strictly causal relationships. However, given that a
controlled trial in which patients would be randomized
on quality of pre-dialysis care is clearly impractical for
ethical reasons, our study is of value. Second, almost
one third of included patients did not complete the
HRQoL questionnaire. Nevertheless, given the relatively
minor differences (only age) between respondents and
non-respondents, we can assume that these non-
responses probably did not introduce a systematic bias
that would distort our conclusions. Third, HRQoL was
measured up to three months after the start of dialysis.
This may reflect care received on dialysis as much as
pre-dialysis care, but sensitivity analyses including only
patients who completed the HRQoL within the first
10 days after the dialysis onset did not change the
results. Fourth, despite adjustment for the main patient
characteristics known to be associated with HRQoL in
CKD, residual confounding due to the lack of data on
variables - such as socioeconomics parameters - for
which we could not account may still exist. Fifth, several
aspects of quality of pre-dialysis care were taken into
account in our study, but not all. For example, the quality
of dialysis preparation and counseling was not considered
here.
Concerning management of CKD, clinicians have
always recognized the importance of diagnosing func-
tional impairments. Our study provides finally an accu-
rate measure of patient-perceived health status at
dialysis onset, and highlights the impact of quality of
therapeutic practices and early nephrology referral on
HRQoL, independently of the number of consultations.
Conclusions
To our knowledge, this observational study is the first to
explore the association between the quality of pre-ESRD
nephrological care and HRQoL at dialysis onset. The
mental component, but not the physical, is significantly
influenced by the quality of pre-dialysis nephrological
care, evaluated across five therapeutic aspects. Late refer-
ral to a nephrologist is associated with poor HRQoL
(symptoms/problems and effects of disease dimensions).
Therefore, CKD disease management incorporating psy-
chological support should be emphasized.
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